G7 Health Topics: Plenty Of Talk, Limited Action
This article was originally published in PharmAsia News
Pushed in part by host Japan, health issues including antimicrobial resistance and incentives for drug R&D in this and other sectors formed an important part of the agenda at last week's G7 meeting. But while there was plenty of recognition of important issues, concrete progress was limited.
You may also be interested in...
In line with similar initiatives by Japan on other regulatory fronts, the country's Agency for Medical Research and Development is building up its partnerships and presence in Asia.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.